A total of 18 US patent applications have been filed under SSV Therapeutics LLC, and Jiva Pharma, Inc. in areas of metabolic diseases for lowering cholesterol, triglycerides, and anti-diabetics; and treating CNS diseases of fibromyalgia; early stages of Alzheimer’s, and Wilson’s disease of elevated copper levels. Thirteen US patents have been issued to Dr. Goel as sole inventor in these areas. Three applications are pending
In the past 5 years, Dr. Goel has assiduously pursued novel small molecules to topically treat infections caused by herpes hsv-1, and hsv-2, and especially, the zoster varicella virus, which causes chickenpox in children. In spite of the vaccines for it there are up to 6 million VZV infection worldwide.
The lead compound is JIVA-0054-2 (JP-0054) which has shown potent activity in in vitro and in vivo models.
The following is the timeline for JP-0054:
In vitro cellular antiviral activity completed against HSV-1, 2, and VZV.
In vivo mice activity confirmed against herpes keratitis. Comparable to Viraoptic™ but less toxic.
In vivo mice, or guinea pigs testing against genital herpes to be completed using a prototype formulation; 06/30/2020
Raise venture funding, and bring in a BOD, hire a team of CEO, Finance, Clinical Director, and Directors of Clinical supplies, and Regulatory Filings, and Business Director.
A 250 g GLP batch to be available by 05/30/2020
Apply for a generic name for JP-0054
File an IND for at least one indication by 12/01/2020 and launch a Phase1-2 study in 01/2021.